Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide (GLP)-1 receptor agonists are the cornerstone in the treatment of hyperglycemia in many people suffering from type 2 diabetes (T2D). These drugs have potent glucose-lowering actions and, additionally, lower body weight through satiety induction while reducing blood pressure and dyslipidemia. Partly through these actions, GLP-1 receptor agonism was shown to reduce cardiovascular disease (CVD) in people with T2D with previous CVD or at high-risk thereof. In these cardiovascular safety trials, in secondary or exploratory analyses, GLP-1 receptor agonists were also shown to reduce macro-albuminuria, an accepted surrogate marker for diabetic kidney disease (DKD), a condition that still represents a major unmet medical need. In this review we will discuss the evidence which suggests renoprotection induced by GLP-1 receptor agonists and the potential mechanisms that may be involved. These include mitigation of hyperglycemia, overweight and insulin resistance, systemic and glomerular hypertension, dyslipidemia, sodium retention, inflammation and renal hypoxia. The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs reduce progression to macro-albuminuria and lead to (subtle) reductions in the decline in renal function”
From Safety of Semaglutide (2021) · cites this paper as [118]
In the citing paper
“Furthermore, GLP-1RA inhibits mesangial expansion, reduces the endothelial expression of profibrotic molecules and increases the availability of intraglomerular nitric oxide, thus slowing the progression of DKD [37, 38].”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60595-4 · Cited by 2,213
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies
Strazzullo, P., D'Elia, L., Kandala, N.-B., & Cappuccio, F. P. (2009) · BMJ · doi:10.1136/bmj.b4567 · Cited by 1,580
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740
Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30104-9 · Cited by 648
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Fine, L. G., & Norman, J. T. (2008) · Kidney International · doi:10.1038/ki.2008.350 · Cited by 515
Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Single-Nephron Glomerular Filtration Rate in Healthy Adults
Denic, A., Mathew, J., Lerman, L. O., Lieske, J. C., Larson, J. J., Alexander, M. P., Poggio, E., Glassock, R. J., & Rule, A. D. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614329 · Cited by 387
van Bommel, E. J. M., Muskiet, M. H. A., van Baar, M. J. B., Tonneijck, L., Smits, M. M., Emanuel, A. L., Bozovic, A., Danser, A. H. J., Geurts, F., Hoorn, E. J., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.013 · Cited by 363
Liraglutide in Children and Adolescents with Type 2 Diabetes
Tamborlane, W. V., Barrientos-Pérez, M., Fainberg, U., Frimer-Larsen, H., Hafez, M., Hale, P. M., Jalaludin, M. Y., Kovarenko, M., Libman, I., Lynch, J. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903822 · Cited by 357
Fatty Kidney, Hypertension, and Chronic Kidney Disease: The Framingham Heart Study
Foster, M. C., Hwang, S.-J., Porter, S. A., Massaro, J. M., Hoffmann, U., & Fox, C. S. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.175315 · Cited by 356
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30192-5 · Cited by 351
(2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70156-1 · Cited by 319
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
Perkovic, V., Heerspink, H. L., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M. E., Hamet, P., Marre, M., et al. (2013) · Kidney International · doi:10.1038/ki.2012.401 · Cited by 316
Muskiet, M. H. A., Tonneijck, L., Huang, Y., Liu, M., Saremi, A., Heerspink, H. J. L., & van Raalte, D. H. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30268-7 · Cited by 259
Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E. (2016) · Diabetes Care · doi:10.2337/dc14-2883 · Cited by 235
SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome
van Bommel, E. J. M., Muskiet, M. H. A., Tonneijck, L., Kramer, M. H. H., Nieuwdorp, M., & van Raalte, D. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06080616 · Cited by 222
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
Karg, M. V., Bosch, A., Kannenkeril, D., Striepe, K., Ott, C., Schneider, M. P., Boemke-Zelch, F., Linz, P., Nagel, A. M., Titze, J., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0654-z · Cited by 182
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
Muskiet, M. H. A., Smits, M. M., Morsink, L. M., & Diamant, M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.272 · Cited by 181
The Renal Pathology of Obesity
Tsuboi, N., Okabayashi, Y., Shimizu, A., & Yokoo, T. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.01.007 · Cited by 174
The New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
Lytvyn, Y., Bjornstad, P., van Raalte, D. H., Heerspink, H. L., & Cherney, D. Z. I. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz010 · Cited by 165
Self-citationCarraro-Lacroix, L. R., Malnic, G., & Girardi, A. C. C. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00082.2009 · Cited by 161
Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Wu, Y., Yan, P., Smith, U., Yki-Järvinen, H., Diamant, M., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.04.024 · Cited by 132
Li, K., Zou, J., Ye, Z., Di, J., Han, X., Zhang, H., Liu, W., Ren, Q., & Zhang, P. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163907 · Cited by 127
Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetologia · doi:10.1007/s00125-016-3938-z · Cited by 126
Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., ter Wee, P. M., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes Care · doi:10.2337/dc16-1371 · Cited by 113
ACE inhibitors and statins in adolescents with type 1 diabetes
Marcovecchio, M. L., Chiesa, S. T., Bond, S., Daneman, D., Dawson, S., Donaghue, K. C., Jones, T. W., Mahmud, F. H., Marshall, S. M., Neil, H. A. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703518 · Cited by 112
Wang, C., Li, L., Liu, S., Liao, G., Li, L., Chen, Y., Cheng, J., Lu, Y., & Liu, J. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193473 · Cited by 110
Effects of GLP-1 in the Kidney
Skov, J. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9287-7 · Cited by 107
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12601 · Cited by 102
Role of the Immune System in Diabetic Kidney Disease
Hickey, F. B., & Martin, F. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0984-6 · Cited by 96
Lipotoxicity in Diabetic Nephropathy: The Potential Role of Fatty Acid Oxidation
Murea, M., Freedman, B. I., Parks, J. S., Antinozzi, P. A., Elbein, S. C., & Ma, L. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08160910 · Cited by 95
Asmar, A., Simonsen, L., Asmar, M., Madsbad, S., Holst, J. J., Frandsen, E., Moro, C., Jonassen, T., & Bülow, J. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00429.2014 · Cited by 93 · cited 1×
“In non-diabetic mice, GLP-1 infusion increased GFR by reducing preglomerular resistance [20], an observation that could potentially explain the physiological increase in GFR observed in the postprandial compared to the fasting state, although human studies infusing GLP-1 peptide could not replicate this observation [2…”
ResultBjornstad, P., Nehus, E. J., ghormli, L. K. E., Bacha, F. F., Libman, I. M., McKay, S. V., Willi, S. M., Laffel, L. M., Arslanian, S. A., Nadeau, K. J., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.07.015 · Cited by 92
Self-citationPleiotropic effects of type 2 diabetes management strategies on renal risk factors
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Heerspink, H. J. L., & van Raalte, D. H. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00030-3 · Cited by 90
Renal sinus fat and renal hemodynamics: a cross-sectional analysis
Spit, K. A., Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Joles, J. A., de Boer, A., & van Raalte, D. H. (2020) · Magnetic Resonance Materials in Physics, Biology and Medicine · doi:10.1007/s10334-019-00773-z · Cited by 83
A different view on sodium balance
Titze, J. (2015) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000085 · Cited by 81
Renal Biopsy in Type 2 Diabetic Patients
Espinel, E., Agraz, I., Ibernon, M., Ramos, N., Fort, J., & Serón, D. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4050998 · Cited by 78
Carey, R. M. (1978) · Circulation Research · doi:10.1161/01.res.43.1.19 · Cited by 76
Time course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment
von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F., & Rossing, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12594 · Cited by 73
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12985 · Cited by 62
Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
BETHEL, M. A., MENTZ, R. J., MERRILL, P., BUSE, J. B., CHAN, J. C., GOODMAN, S. G., IQBAL, N., JAKUBONIENE, N., KATONA, B. G., LOKHNYGINA, Y., et al. (2018) · Diabetes · doi:10.2337/db18-522-p · Cited by 54
Bjornstad, P., Hughan, K., Kelsey, M. M., Shah, A. S., Lynch, J., Nehus, E., Mitsnefes, M., Jenkins, T., Xu, P., Xie, C., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0708 · Cited by 51
Self-citationLiraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice
Bisgaard, L. S., Bosteen, M. H., Fink, L. N., Sørensen, C. M., Rosendahl, A., Mogensen, C. K., Rasmussen, S. E., Rolin, B., Nielsen, L. B., & Pedersen, T. X. (2016) · PLOS ONE · doi:10.1371/journal.pone.0168396 · Cited by 47
Hung, C., Tsai, J., Kuo, H., Chang, J., Hwang, S., & Chen, H. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.110 · Cited by 28
Liraglutide in children and adolescents with type 2 diabetes
Tamborlane, W. V., Pérez, M. B., Fainberg, U., Frimer‐Larsen, H., Hafez, M., Pm, H., Jalaludin, M., Коваренко, М. А., Libman, I. M., Lynch, J. L., et al. (2019) · Yearbook of pediatric endocrinology · doi:10.1530/ey.16.12.5 · Cited by 18
Moorhead, J. F., Brunton, C., & Varghese, Z. (1997) · PubMed · Cited by 11
Renal tubular solute transport and oxygen consumption: insights from computational models
Layton, A. T., & Vallon, V. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000435 · Cited by 7
Bjornstad, P., Hughan, K. S., Kelsey, M. M., SHAH, A. S., Lynch, J. L., Nehus, E. J., Mitsnefes, M. M., Jenkins, T. M., Xu, P., Xie, C., et al. (2019) · Diabetes · doi:10.2337/db19-123-or · Cited by 1
Self-citation
Cited by
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.001 · Cited by 104
Tong, M., Luo, L.-Z., Xue, P., Han, Y.-H., Wang, L., Zhuge, D., Yao, Q., Chen, B., Zhao, Y., & Xu, H. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.01.007 · Cited by 72
Slieker, R. C., van der Heijden, A. A. W. A., Siddiqui, M. K., Langendoen‐Gort, M., Nijpels, G., Herings, R. M. C., Feenstra, T., Moons, K. G. M., Bell, S., Elders, P. J. M., et al. (2021) · BMJ · doi:10.1136/bmj.n2134 · Cited by 70
Metadata
- Authors
- Mosterd, C. M., Bjornstad, P., & van Raalte, D. H.
- Affiliations
- Amsterdam University Medical Centers (NL)
- University of Colorado Anschutz (US)
- Venue
- Journal of Nephrology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04-30
- Volume
- 33
- Issue
- 5
- Pages
- 965-975
- ISSN
- 1121-8428 (ISSN-L)
- 1724-6059
- PMC
- PMC7560915
- OpenAlex
- W3023544430
- Cited by
- 56
- References
- 67
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 12 · 2023: 8 · 2022: 11 · 2021: 7 · 2020: 3
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Nephrology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- GLP-1 receptor agonists, diabetic nephropathy, renal protection, semaglutide, type 2 diabetes, albuminuria, hyperglycemia, insulin resistance, glomerular hypertension, dyslipidemia, sodium retention, renal inflammation, renal hypoxia, FLOW trial
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Pharmaceutical Preparations, Humans, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.